Immunotherapy of cerebrovascular amyloidosis in a transgenic mouse model
- 29 February 2012
- journal article
- Published by Elsevier BV in Neurobiology of Aging
- Vol. 33 (2), 432.e1-432.e13
- https://doi.org/10.1016/j.neurobiolaging.2011.01.006
Abstract
No abstract availableKeywords
Funding Information
- HFSP organization
- Dana Foundation
- NIH (NIA AG027437)
- United States-Israel Bi-National Science Foundation
This publication has 53 references indexed in Scilit:
- Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's diseaseNature Medicine, 2009
- Selective targeting of perivascular macrophages for clearance of β-amyloid in cerebral amyloid angiopathyProceedings of the National Academy of Sciences of the United States of America, 2009
- A nasal proteosome adjuvant activates microglia and prevents amyloid depositionAnnals of Neurology, 2008
- Clearance of amyloid-β by circulating lipoprotein receptorsNature Medicine, 2007
- Brain-Derived Neurotrophic Factor: A Newly Described Mediator of AngiogenesisTrends in Cardiovascular Medicine, 2007
- Stage-dependent BDNF serum concentrations in Alzheimer’s diseaseJournal of Neural Transmission, 2005
- β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's DiseaseJournal of Neuroscience, 2005
- The levels of soluble amyloid beta in different high density lipoprotein subfractions distinguish Alzheimer's and normal aging cerebrospinal fluid: implication for brain cholesterol pathology?Neuroscience Letters, 2001
- Hereditary Cerebral Hemorrhage with Amyloidosis‐Dutch Type (HCHWA‐D): I ‐ A Review of Clinical, Radiologic and Genetic AspectsBrain Pathology, 1996
- Cerebral Hemorrhage from Amyloid Angiopathy and Coronary ThrombolysisNeurosurgery, 1992